Skip to content
DataLookout
Menu

AutonomyNCT04619420

A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease

StatusTerminated
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 75 versions: 32 with changes below, 18 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 5, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Primary endpoint revised
    • Secondary endpoints: 21 to 25
    • Site details revised at 4 of 122 sites
  2. Stopped Trial terminated Sponsor's reason: Posdinemab did not achieve statistical significance in slowing clinical decline
    • Study completion date changed from estimate of Mar 8, 2026 to Mar 3, 2026
    v74
  3. Minor Study sites revised (122)v73
  4. Minor Study completion date: Dec 30, 2032 to Mar 8, 2026v72
  5. Minor Primary completion date changed from estimate of Feb 27, 2026 to Oct 17, 2025v70
Show 27 earlier versionsHide 27 earlier versions
  1. Minor Site details revised at 1 of 122 sitesv63
  2. Minor Study sites revised (122)v58
  3. Minor Site details revised at 2 of 122 sitesv56
  4. Minor Study sites revised (122)v54
  5. Minor Study sites revised (122)v52
  6. Minor Primary completion date: Nov 28, 2025 to Feb 27, 2026
    • Study sites revised (122)
    v49
  7. Minor Site details revised at 1 of 122 sitesv48
  8. Notable Primary completion date: Mar 7, 2025 to Nov 28, 2025
    • Secondary endpoints revised (21)
    v47
  9. Minor Study sites revised (122)v46
  10. Minor Study sites revised (122)v45
  11. Minor Study completion date: Dec 1, 2025 to Dec 30, 2032v44
  12. Minor Secondary endpoints: 20 to 21
    • Site details revised at 1 of 122 sites
    • Study arms: 2 to 3
    v43
  13. Minor Study completion date: Nov 5, 2025 to Dec 1, 2025v42
  14. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 480 to confirmed 523
    • Site details revised at 122 of 122 sites
    v41
  15. Minor Study sites revised (122)v40
  16. Minor Site details revised at 2 of 122 sitesv39
  17. Minor Site details revised at 8 of 122 sitesv38
  18. Minor Study sites revised (122)v37
  19. Minor Site details revised at 2 of 122 sitesv36
  20. Minor Enrollment target: 420 to 480
    • Study sites: 144 to 122
    v34
  21. Minor Site details revised at 1 of 144 sitesv33
  22. Minor Study sites revised (144)v31
  23. Minor Site details revised at 5 of 144 sitesv30
  24. Minor Site details revised at 1 of 144 sitesv29
  25. Minor Study sites revised (144)v28
  26. Minor Site details revised at 7 of 144 sitesv27
  27. Minor Site details revised at 10 of 144 sitesv26
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Double-blind (DB) Treatment Period: Change From Baseline in Integrated Alzheimer's Disease Rating Scale for Mild Cognitive Impairment (iADRS-MCI) Total Score at Week 104
Timeframe: Baseline (Day 1), Week 104

Secondary (25)

Double-blind (DB) Treatment Period: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive, 13-item Version (ADAS-Cog13) Total Score at Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI) Total Score at Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at Week 88
Double-blind (DB) Treatment Period: Change From Baseline in Each of the 5 Individuals RBANS Indices at Week 88
Double-blind (DB) Treatment Period: Change From Baseline in Each of the 12 Subtests Comprising the RBANS at Week 88
Show 20 moreShow less
Double-blind (DB) Treatment Period: Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Week 104
Double-blind (DB) Treatment Period: Percentage of Participants With Progression From Clinical Dementia Rating-Global Score (CDR-GS) 0 to 0.5 or Higher, 0.5 to 1 or Higher, and 1 to 2 or Higher
Double-blind (DB) Treatment Period: Change From Baseline in Brain Tau Burden as Measured by Tau Positron Emission Tomography (PET) at Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Cerebrospinal Fluid (CSF) Concentrations of Total, Free, and Bound p217+Tau Fragments at Week 104
Double-blind (DB) Treatment Period: Cerebrospinal Fluid (CSF) Concentrations of JNJ-63733657
Double-blind (DB) Treatment Period: Serum Concentrations of JNJ-63733657
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent JNJ-63733657 Antidrug Antibodies (ADAs) in Serum
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)
Double-blind (DB) Treatment Period: Number of Participants Who Discontinued Study Treatment Due to AEs
Double-blind (DB) Treatment Period: Change From Baseline in 12-lead Electrocardiogram (ECG) Parameter: ECG Mean Heart Rate Supine
Double-blind (DB) Treatment Period: Change From Baseline in 12-lead ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcB Interval, QTcF Interval, QTcL Interval, and RR Interval
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormalities in Laboratory Parameters
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormal Findings in Neurological Examination
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormal Findings in Physical Examination
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Potentially Clinically Significant Vital Signs
Double-blind (DB) Treatment Period: Number of Participants With Brain Magnetic Resonance Imaging (MRI) Safety Findings
Double-blind (DB) Treatment Period: Number of Participants With Shift From Baseline in Suicidal Ideation or Suicidal Behavior as Assessed by Columbia Suicidality Severity Rating Scale (C-SSRS)

Arms and interventions

JNJ-63733657 Low-doseExperimental

Participants will receive single dose of JNJ-63733657 low-dose administered by intravenous (IV) infusion every 4 weeks during the double-blind treatment period. Participants will have an option to continue with the long-term extension (LTE) phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period.

JNJ-63733657 High-doseExperimental

Participants will receive single dose of JNJ-63733657 high-dose administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period.

PlaceboPlacebo comparator

Participants will receive single dose of matching placebo to JNJ-63733657 administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will be re-randomized in a 1:1 ratio to receive either JNJ-63733657 low-dose or JNJ-63733657 high-dose during the LTE treatment period.

Drugs: JNJ-63733657, Placebo

Sites

122 sites in 10 countries

United States 55, Japan 22, France 9, Spain 9, Belgium 8, Australia 7, Canada 5, Netherlands 4, United Kingdom 2, Sweden 1